HLS THERAPEUTICS INC (HLS.CA) Stock Fundamental Analysis
TSX:HLS - Toronto Stock Exchange - CA40390B1094 - Common Stock - Currency: CAD
HLS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 34 industry peers in the Pharmaceuticals industry. While HLS seems to be doing ok healthwise, there are quite some concerns on its profitability. HLS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year HLS has reported negative net income.
HLS had a positive operating cash flow in the past year.
HLS had negative earnings in each of the past 5 years.
In the past 5 years HLS always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of HLS (-11.68%) is comparable to the rest of the industry.
HLS has a Return On Equity (-26.92%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.68% | ||
| ROE | -26.92% | ||
| ROIC | N/A |
ROA(3y)-11.74%
ROA(5y)-9%
ROE(3y)-24.86%
ROE(5y)-18.35%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HLS has a Gross Margin of 83.05%. This is amongst the best in the industry. HLS outperforms 100.00% of its industry peers.
HLS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for HLS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.05% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.41%
GM growth 5Y-2.67%
2. Health
2.1 Basic Checks
HLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HLS has been reduced compared to 1 year ago.
HLS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, HLS has an improved debt to assets ratio.
2.2 Solvency
HLS has an Altman-Z score of -0.73. This is a bad value and indicates that HLS is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.73, HLS perfoms like the industry average, outperforming 52.94% of the companies in the same industry.
The Debt to FCF ratio of HLS is 5.94, which is a neutral value as it means it would take HLS, 5.94 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 5.94, HLS is in the better half of the industry, outperforming 73.53% of the companies in the same industry.
HLS has a Debt/Equity ratio of 0.87. This is a neutral value indicating HLS is somewhat dependend on debt financing.
HLS has a worse Debt to Equity ratio (0.87) than 73.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.87 | ||
| Debt/FCF | 5.94 | ||
| Altman-Z | -0.73 |
ROIC/WACCN/A
WACC8.24%
2.3 Liquidity
A Current Ratio of 1.43 indicates that HLS should not have too much problems paying its short term obligations.
HLS has a Current ratio of 1.43. This is comparable to the rest of the industry: HLS outperforms 47.06% of its industry peers.
HLS has a Quick Ratio of 1.12. This is a normal value and indicates that HLS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.12, HLS is in line with its industry, outperforming 52.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 33.72% over the past year.
HLS shows a decrease in Revenue. In the last year, the revenue decreased by -6.62%.
The Revenue has been growing slightly by 0.88% on average over the past years.
EPS 1Y (TTM)33.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
Revenue 1Y (TTM)-6.62%
Revenue growth 3Y-1.91%
Revenue growth 5Y0.88%
Sales Q2Q%1.2%
3.2 Future
The Earnings Per Share is expected to grow by 22.85% on average over the next years. This is a very strong growth
Based on estimates for the next years, HLS will show a small growth in Revenue. The Revenue will grow by 7.26% on average per year.
EPS Next Y52.22%
EPS Next 2Y28.76%
EPS Next 3Y21.38%
EPS Next 5Y22.85%
Revenue Next Year1.06%
Revenue Next 2Y5.86%
Revenue Next 3Y9.83%
Revenue Next 5Y7.26%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for HLS. In the last year negative earnings were reported.
Also next year HLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HLS is valued a bit cheaper than 64.71% of the companies in the same industry.
HLS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. HLS is cheaper than 82.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.8 | ||
| EV/EBITDA | 11.46 |
4.3 Compensation for Growth
A more expensive valuation may be justified as HLS's earnings are expected to grow with 21.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.76%
EPS Next 3Y21.38%
5. Dividend
5.1 Amount
No dividends for HLS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:HLS (6/17/2025, 7:00:00 PM)
4.97
-0.02 (-0.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners45.35%
Inst Owner ChangeN/A
Ins Owners0.52%
Ins Owner ChangeN/A
Market Cap157.20M
Analysts75.56
Price Target5.74 (15.49%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-24.33%
Min EPS beat(2)-36.79%
Max EPS beat(2)-11.88%
EPS beat(4)1
Avg EPS beat(4)-12.53%
Min EPS beat(4)-36.79%
Max EPS beat(4)0.99%
EPS beat(8)1
Avg EPS beat(8)-47.19%
EPS beat(12)1
Avg EPS beat(12)-57.61%
EPS beat(16)3
Avg EPS beat(16)-39.16%
Revenue beat(2)0
Avg Revenue beat(2)-1.08%
Min Revenue beat(2)-1.99%
Max Revenue beat(2)-0.17%
Revenue beat(4)1
Avg Revenue beat(4)-1.96%
Min Revenue beat(4)-5.77%
Max Revenue beat(4)0.1%
Revenue beat(8)2
Avg Revenue beat(8)-3.43%
Revenue beat(12)2
Avg Revenue beat(12)-4.67%
Revenue beat(16)3
Avg Revenue beat(16)-4.8%
PT rev (1m)-8.54%
PT rev (3m)-7.02%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.76%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.83%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.04 | ||
| P/FCF | 10.8 | ||
| P/OCF | 10.76 | ||
| P/B | 1.74 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.46 |
EPS(TTM)-0.77
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)0.46
FCFY9.26%
OCF(TTM)0.46
OCFY9.29%
SpS2.43
BVpS2.86
TBVpS-2.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.68% | ||
| ROE | -26.92% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.05% | ||
| FCFM | 18.91% |
ROA(3y)-11.74%
ROA(5y)-9%
ROE(3y)-24.86%
ROE(5y)-18.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.41%
GM growth 5Y-2.67%
F-Score6
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.87 | ||
| Debt/FCF | 5.94 | ||
| Debt/EBITDA | 4.11 | ||
| Cap/Depr | 0.15% | ||
| Cap/Sales | 0.06% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 76.2% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | -0.73 |
F-Score6
WACC8.24%
ROIC/WACCN/A
Cap/Depr(3y)0.36%
Cap/Depr(5y)20.34%
Cap/Sales(3y)0.19%
Cap/Sales(5y)11.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
EPS Next Y52.22%
EPS Next 2Y28.76%
EPS Next 3Y21.38%
EPS Next 5Y22.85%
Revenue 1Y (TTM)-6.62%
Revenue growth 3Y-1.91%
Revenue growth 5Y0.88%
Sales Q2Q%1.2%
Revenue Next Year1.06%
Revenue Next 2Y5.86%
Revenue Next 3Y9.83%
Revenue Next 5Y7.26%
EBIT growth 1Y35.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year287.73%
EBIT Next 3Y66.38%
EBIT Next 5Y41.74%
FCF growth 1Y-28.87%
FCF growth 3Y-20.24%
FCF growth 5Y-19.65%
OCF growth 1Y-29.16%
OCF growth 3Y-21.32%
OCF growth 5Y-21.24%